Published in Vaccine Weekly, November 26th, 2003
ID Biomedical sold a total of 5,800,000 units at a price of US$17.37 per unit for total gross proceeds of US$100,746,000. Each unit consists of one common share and one-half of one common share purchase warrant. Subject to adjustment, each whole warrant entitles the holder thereof to purchase an additional common share at the price of US$25.00 for a period of 4 years after the closing date of the offering.
The net proceeds of the offering will be used for the clinical and manufacturing development of ID Biomedical's FluINsure and StreptAvax vaccines, working...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.